CPI 203

• Supplier: Tocris Bioscience
• Catalog: 1028
• Prices: $299.00
• Sizes: 10 mg
• Function Type: Inhibitor
• Cas Number: 1446144-04-2
• Chemical Name: (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide
• Formula: C19H18ClN5OS
• Molecular Weight: 399.9
• Purity: >98 %
• Description: BET bromodomain inhibitor. Downregulates Myc expression, causes G 1 cell cycle arrest and attenuates cell proliferation in human pancreatic neuroendocrine tumors. Arrests the growth of T cell acute lymphoblastic leukemia cells in vitro (EC 50 = 91.2 nM). Also enhances the antitumor effect of rapamycin (Cat. No. 1292) in vitro and attenuates rapamycin induced Akt activation. Orally bioavailable.

Product References

The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by - The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by

King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P, Aranda-Orgilles B, Perez-Garcia A, Shi J, Vakoc C, Sandy P, Shen SS, Ferrando A, Aifantis I. Cell. 2013 Jun 20;153(7):1552-66.

The bromodomain and extra-terminal inhibitor CPI203 enhances the - The bromodomain and extra-terminal inhibitor CPI203 enhances the

Wong C, Laddha SV, Tang L, Vosburgh E, Levine AJ, Normant E, Sandy P, Harris CR, Chan CS, Xu EY. Cell Death Dis. 2014 Oct 9;5:e1450.